Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Aprea Therapeutics. The associated price target remains the same with $10.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors related to Aprea Therapeutics’ ongoing research and development efforts. Despite facing challenges in the synthetic lethality space, Aprea’s WEE1i and ATRi candidates have shown promising progress in early-stage studies. The company has managed to maintain sufficient funding to reach key milestones, which are expected to act as catalysts for future growth.
Aprea’s continuous dosing strategy has demonstrated enhanced safety and tolerability profiles, along with early efficacy signals, particularly in its WEE1i program. The company’s oral WEE1 inhibitor, APR-1051, has shown positive safety results and early disease control signals even at subtherapeutic doses. This approach contrasts with competitors who have faced significant toxicity issues, necessitating less effective intermittent dosing. These developments, along with anticipated updates in the second half of 2025, support the positive outlook and Buy rating for Aprea Therapeutics.
APRE’s price has also changed dramatically for the past six months – from $3.430 to $1.700, which is a -50.44% drop .